Cochrane · systematic review · CD010636
Leukotriene inhibitors for bronchiolitis in infants and young children
Liu, F, Ouyang, J, Sharma, AN, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 40%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Montelukast versus placebo for bronchiolitis in infants and young children
Population: infants and young children with bronchiolitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Length of hospital stay Montelukast vs placebo | no estimate extracted | 2 studies · 136 participants | Low Downgraded: imprecision, inconsistency |
All‐cause mortality Deaths Montelukast vs placebo | RR 2.51 [0.12, 52.16] | 1 study · 952 participants | Ungraded |
Clinical severity score (day 2) Montelukast vs placebo | no estimate extracted | 2 studies · 136 participants | Low Downgraded: imprecision, inconsistency |
Clinical severity score (day 3) Montelukast vs placebo | no estimate extracted | 2 studies · 132 participants | Low Downgraded: imprecision |
Clinical adverse effects Montelukast vs placebo | no estimate extracted | 3 studies · 1063 participants | Ungraded |